-
What’s it like to work with us?
What’s it like to work with TherapeutAix, you may ask? While we have quite a bit of information on our…
-
One Project, Many Customers
In theory, the drug discovery and development pathway is not complicated. You start with an exciting idea where biology meets…
-
The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services…
-
Reflections from ECM2022, Copenhagen, July 2022
The Extracellular Matrix Pharmacology Symposium 2022, aka ECM2022, took place in Copenhagen a couple of weeks ago. The focus of…
-
Workshops reloaded
At TherapeutAix, we have a number of tools to support our clients. In addition to, for example, the MIRIADD approach…
-
Rare and common diseases – where’s the link?
It’s Rare Disease Day. Last year on our blog, we looked at how rare diseases can help better our understanding…
-
Adoption and cost-effectiveness of IPF therapies
Fibrotic remodelling occurs in many diseases. Thinking about idiopathic pulmonary fibrosis (IPF) as a ‘purely’ fibrotic condition, with currently unknown…
-
Happy Birthday TherapeutAix! Celebrating our third year
As TherapeutAix celebrates our three-year birthday this month, we thought it would be a great opportunity to take a look…
-
Reflections from ERS
Having joined a wide range of sessions at the virtual ERS meeting last week, we were keen to share some of our…
-
Working in Respiratory Diseases – Our Capabilities
As this year’s ERS meeting is about to kick off, we’ve looked back at the last three years at TherapeutAix…
